Application of susceptibility weighted imaging in the diagnosis and differential diagnosis of intracranial metastatic tumors

Abstract

Abstract:

ObjectiveTo explore the value of susceptibility weighted imaging (SWI) in differential diagnosis of intracranial metastatic tumors.MethodsSixty-three patients with intracranial metastatic tumors (primary tumors of lung cancer, breast cancer, kidney cancer, rectal cancer, bladder cancer and melanoma) and glioblastomas in People's Hospital of Xinjiang Uygur Autonomous Region from January 2018 to April 2020 were collected, and the intratumoral susceptibility signal intensity (ITSS) was evaluated semi-quantitatively. The grading characteristics of ITSS of metastatic tumors and glioblastomas were compared.ResultsAmong the 81 intracranial metastatic tumors, 36 (44.4%) were grade 0, 25 (30.9%) were grade Ⅰ, 14 (17.3%) were grade Ⅱ and 6 (7.4%) were grade Ⅲ. Among the 27 glioblastomas, 27 (100%) were grade Ⅱ-Ⅲ. Grade 0-Ⅰ metastatic tumors of lung cancer accounted for 73.6% (28/38). Grade 0 metastatic tumors of breast cancer accounted for 84.6% (22/26). Grade Ⅱ metastatic tumor of kidney cancer accounted for 5/6. Grade 0-Ⅰ metastatic tumors of rectal cancer accounted for 4/5. Grade Ⅲ glioblastomas accounted for 77.8% (21/27). The difference of ITSS classification between intracranial metastatic tumors and glioblastomas was statistically significant (Z=7.013,P<0.001). According to the receiver operating characteristic curve analysis, the sensitivity and specificity of ITSS ≤grade Ⅰ were 100% and 75.3% respectively, and the area under the curve was 0.936 (95%CI: 0.891-0.980,P<0.001).ConclusionThe patients with intracranial metastatic tumor usually present ITSS grade 0-Ⅰ, and the patients with glioblastoma usually present ITSS grade Ⅱ-Ⅲ. SWI has a certain value for differential diagnosis of intracranial metastatic tumors.

Key words:Neoplasm metastasis,Glioblastoma,Susceptibility weighted imaging

Wang Hui, Liu Rong, He Juan, Batuer Tuerdi, Yu Taifei, Aihemaiti Tuohuti. Application of susceptibility weighted imaging in the diagnosis and differential diagnosis of intracranial metastatic tumors[J]. Journal of International Oncology, 2020, 47(12): 712-715.

Figures/Tables7

肿瘤类型	0级	Ⅰ级	Ⅱ级	Ⅲ级
肺腺癌	10	12	2	4
肺鳞状细胞癌	0	2	2	0
肺小细胞癌	0	4	2	0
肺大细胞癌	0	0	0	2
乳腺癌	22	3	1	0
肾癌	0	1	5	0
直肠癌	2	2	1	0
膀胱癌	1	0	1	0
黑色素瘤	1	1	0	0
胶质母细胞瘤	0	0	6	21
合计	36	25	20	27

组别	0级	Ⅰ级	Ⅱ级	Ⅲ级
颅内转移瘤(n=81)	36(44.4)	25(30.9)	14(17.3)	6(7.4)
胶质母细胞瘤(n=27)	0(0)	0(0)	6(22.2)	21(77.8)
Z值	7.013
P值	<0.001

References10

[1]	游小江. 首发神经系统症状的肺癌脑转移瘤31例临床分析[J]. 中外医学研究, 2012,10(17):191-192. DOI: 10.3969/j.issn.1674-6805.2012.17.143.
[2]	Zhang W, Zhao J, Guo D, et al. Application of susceptibility weighted imaging in revealing intratumoral blood products and grading gliomas[J]. J Radiol, 2010,91(4):485-490. DOI: 10.1016/s0221-0363(10)70063-9.
[3]	陈文锦, 林祺, 陈金银, 等. 高分辨率磁敏感加权像对颅内肿瘤微血管的研究[J]. 中国医学计算机成像杂志, 2012,18(4):294-297. DOI: 10.3969/j.issn.1006-5741.2012.04.002.
[4]	杜常月, 苗娜, 齐旭红, 等. 磁敏感加权成像及3D-ASL在各级脑胶质瘤分级中的价值[J]. 磁共振成像, 2019,10(9):645-649. DOI: 10.12015/issn.1674-8034.2019.09.002.
[5]	申宝忠, 王丹, 孙夕林, 等. MR磁敏感成像在脑内出血性疾病中的应用[J]. 中华放射学杂志, 2009,43(2):156-160. DOI: 10.3760/cma.j.issn.1005-1201.2009.02.010.
[6]	Xu J, Xu H, Zhang W, et al. Contribution of susceptibility and diffusion weighted magnetic resonance imaging for grading gliomas[J]. Exp Ther Med, 2018,15(6):5113-5118. DOI: 10.3892/etm.2018.6017. doi:10.3892/etm.2018.6017pmid:29805537
[7]	Pinker K, Noebauer-Huhmann IM, Stavrou I, et al. High-resolution contrast-enhanced susceptibility-weighted MR imaging at 3T in patients with brain tumors: correlation with positron-emission tomography and histopathologic findings[J]. AJNR Am J Neuroradiol, 2007,28(7):1280-1286. DOI: 10.3174/ajnr.A0540.
[8]	李伟婷, 李永文, 张洪兵, 等. 基于TCGA数据库的中央型与周围型肺鳞状细胞癌基因表达差异性研究[J]. 中国肺癌杂志, 2019,22(5):280-288. DOI: 10.3779/j.issn.1009-3419.2019.05.04.
[9]	许尧, 张超, 郭旭, 等. 肺癌不同病理类型与骨转移临床特征相关性研究[J]. 中华骨科杂志, 2019,39(6):329-335. DOI: 10.3760/cma.j.issn.0253-2352.2019.06.002.
[10]	王禹, 董潇, 孔垂泽, 等. 不同病理类型肾肿瘤的影像学特点和病理学特点分析[J]. 中华泌尿外科杂志, 2019,40(5):374-379. DOI: 10.3760/cma.j.issn.1000-6702.2019.05.012.

[1]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[2]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing.Progress of radiotherapy in oligometastatic non-small cell lung cancer[J]. Journal of International Oncology, 2024, 51(3): 170-174.
[3]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan.Research progress on the histopathological growth patterns of colorectal liver metastasis[J]. Journal of International Oncology, 2024, 51(2): 114-118.
[4]	Zhang Lu, Jiang Hua, Lin Zhou, Ma Chenying, Xu Xiaoting, Wang Lili, Zhou Juying.Analysis of curative effect and prognosis of immune checkpoint inhibitor in the treatment of recurrent and metastatic cervical cancer[J]. Journal of International Oncology, 2023, 50(8): 475-483.
[5]	Yang Lirong, Wang Yufeng.Construction of machine learning models for predicting the risk of postoperative distant metastasis recurrence in serous ovarian cancer[J]. Journal of International Oncology, 2023, 50(4): 220-226.
[6]	Ma Peihan, Zhang Lingming, Lu Ning, Zhang Mingxin.Effect of anesthesia on the recurrence and metastasis of hepatocellular carcinoma[J]. Journal of International Oncology, 2023, 50(2): 117-121.
[7]	Zhao Jianhao, Duan Yanchao.Research progress in the pathogenesis of extramedullary disease in multiple myeloma[J]. Journal of International Oncology, 2023, 50(1): 55-59.
[8]	Zhang Lu, Zhou Juying, Ma Chenying, Lin Zhou.Advances in immunotherapy for recurrent and metastatic cervical cancer[J]. Journal of International Oncology, 2022, 49(9): 517-520.
[9]	Peng Chen, Xie Yintong, Zhang Xin, Xie Peng.Research progress of maintenance therapy for cervical cancer[J]. Journal of International Oncology, 2022, 49(7): 430-435.
[10]	Lian Haiwei, Yang Shuorui, Liu Renzhong.Mechanism study on regulation of glioblastoma cell proliferation and apoptosis by sciadopitysin combined with CX-4945 through Notch1 pathway[J]. Journal of International Oncology, 2022, 49(6): 321-326.
[11]	Wang Bin, Zhou Jiangyun, Liu Xi.Analysis of the clinical value of different radiotherapy schemes in patients with advanced esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2021, 48(8): 484-488.
[12]	Chi Xiuying, Wang Hongbiao, Li Zhifeng, Lin Yingcheng.Progression in the therapies of relapse or metastatic esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2021, 48(12): 755-759.
[13]	Dai Ang, Sun Qing.CRYAB and tumors[J]. Journal of International Oncology, 2020, 47(6): 351-354.
[14]	Yang Chao, Wang Jianbo, Zhang Juhong, Wang Jialong.Overexpression of miR-125 inhibits proliferation and invasion of nasopharyngeal carcinoma cells by down-regulating FGF-2[J]. Journal of International Oncology, 2020, 47(5): 257-263.
[15]	Zhao Congxuan, Yu Tao.Mining and prediction of glioma-related genes[J]. Journal of International Oncology, 2020, 47(5): 293-296.